Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity - 14/11/17
Abstract |
Background |
Upregulation of kallikreins (KLKs) including KLK5 has been reported in atopic dermatitis (AD). KLK5 has biological functions that include degrading desmosomal proteins and inducing proinflammatory cytokine secretion through protease-activated receptor 2 (PAR2). However, due to the complex interactions between various cells in AD inflamed skin, it is difficult to dissect the precise and multiple roles of upregulated KLK5 in AD skin.
Objective |
We investigated the effect of upregulated KLK5 on the expression of epidermal-related proteins and cytokines in keratinocytes and on skin architecture.
Methods |
Lesional and nonlesional AD skin biopsies were collected for analysis of morphology and protein expression. The relationship between KLK5 and barrier-related molecules was investigated using an ex vivo dermatitis skin model with transient KLK5 expression and a cell model with persistent KLK5 expression. The influence of upregulated KLK5 on epidermal morphology was investigated using an in vivo skin graft model.
Results |
Upregulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin, but not PAR2 were identified in AD skin. PAR2 was increased in response to transient upregulation of KLK5, whereas persistently upregulated KLK5 did not show this effect. Persistently upregulated KLK5 degraded DSG1 and stimulated secretion of IL-8, IL-10, and thymic stromal lymphopoietin independent of PAR2 activity. With control of higher KLK5 activity by the inhibitor sunflower trypsin inhibitor G, restoration of DSG1 expression and a reduction in AD-related cytokine IL-8, thymic stromal lymphopoietin, and IL-10 secretion were observed. Furthermore, persistently elevated KLK5 could induce AD-like skin architecture in an in vivo skin graft model.
Conclusions |
Persistently upregulated KLK5 resulted in AD-like skin architecture and secretion of AD-related cytokines from keratinocytes in a PAR2 independent manner. Inhibition of KLK5-mediated effects may offer potential as a therapeutic approach in AD.
Le texte complet de cet article est disponible en PDF.Key words : Kallikrein 5, atopic dermatitis, skin barrier, serine protease inhibitor, SFTI
Abbreviations used : AD, AOI, AP, DMEM, DSG1, eGFP, FLG, KLK, NS, PAR2, pKC, rKLK5, SFTI-G, TBS, TSLP
Plan
| Supported by Sparks and the Livingstone Fund (Great Ormond Street Hospital Children's Charity) and Biotechnology and Biological Sciences Research Council. |
|
| Disclosure of potential conflict of interest: J. Underwood's, C. Pickard's, P. Friedmann's, and E. Healy's institutions received a grant from Biotechnology and Biological Sciences Research Council for this work. W. Di's institution received a grant from Sparks and the Livingstone Fund for this work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 140 - N° 5
P. 1310 - novembre 2017 Retour au numéro
Article précédent
- Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema
- Martina S. Elias, Heather A. Long, Carla F. Newman, Paul A. Wilson, Andrew West, Paul J. McGill, Keith C. Wu, Michael J. Donaldson, Nick J. Reynolds
- Food protein–induced enterocolitis syndrome in Australia: A population-based study, 2012-2014
- Sam Mehr, Katie Frith, Elizabeth H. Barnes, Dianne E. Campbell, FPIES Study Group ‡ KatrinaAllenElizabethBarnesDianne E.CampbellKatieFrithMikeGoldPreetiJoshiAlysonKakakiosRichardLohSamMehrJanePeakeJoanneSmartPeterSmithMimiTangBrynnWainsteinMelanieWongYvonneZurynski, Katrina Allen, Elizabeth Barnes, Dianne E. Campbell, Katie Frith, Mike Gold, Preeti Joshi, Alyson Kakakios, Richard Loh, Sam Mehr, Jane Peake, Joanne Smart, Peter Smith, Mimi Tang, Brynn Wainstein, Melanie Wong, Yvonne Zurynski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?